타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Tecvayli (teclistamab-cqyv) | Elranatamab | Blinatumomab |
Overview Company | Johnson & Johnson | Pfizer | Amgen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | BCMA × CD3 | FRα | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | Relapsed or refractory multiple myeloma | Multiple Myeloma | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and du | novel mechanisms of action that traditional monoclonal antibodies cannot achieve |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | resistance to available treatments | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
Positioning Development positioning | 5L+ (label), earlier in practice and ongoing trials | — | — |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | targeting both B-cell maturation antigen | targeting CD19/20/22 and engineered chimeric antigen receptor |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. | BCMA-targeted therapies and feasibility in selected high | CD19 expression, whereas cytoplasmic CD22 expression |
Toxicology Animal (cat.) | — | Unknown | — |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | — |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% | 58% | — |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Tecvayli (teclistamab-cqyv) | Elranatamab | Blinatumomab |
Overview Company | Johnson & Johnson | Pfizer | Amgen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | BCMA × CD3 | FRα | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | Relapsed or refractory multiple myeloma | Multiple Myeloma | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and du | novel mechanisms of action that traditional monoclonal antibodies cannot achieve |
Positioning Known limitation | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | resistance to available treatments | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
Positioning Development positioning | 5L+ (label), earlier in practice and ongoing trials | — | — |
MoA Mechanism | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | targeting both B-cell maturation antigen | targeting CD19/20/22 and engineered chimeric antigen receptor |
MoA Biomarker | BCMA expression, MRD negativity, serum free light chain response. | BCMA-targeted therapies and feasibility in selected high | CD19 expression, whereas cytoplasmic CD22 expression |
Toxicology Animal (cat.) | — | Unknown | — |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | — |
Toxicology CRS | CRS ~72%, grade ≥3 ~0.6% | 58% | — |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교